Andlauer Healthcare Group (AND) AI Stock Analysis

• Market Cap: $2.09B
• Dividend Yield: 0.86%
• Average Volume (3M): 73.87K
• Price to Earnings (P/E): 31.0
• Beta (1Y): 0.56
• Revenue Growth: 0.34%
• EPS Growth: 10.40%
• Country: CA
• Employees: 2,380
• Sector: Industrials
• Sector Strength: 83
• Industry: Integrated Freight & Logistics
• EPS (TTM): 0.33
• Shares Outstanding: 18,342,255
• 10 Day Avg. Volume: 60,083
• 30 Day Avg. Volume: 73,867
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 3.38
• Enterprise Value/Gross Profit: 14.77
• Enterprise Value/Ebitda: 12.96
• 1Y Price Target: $58.98
• Price Target Upside: 10.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 76 Outperform
• Price Target: C$59.00 ▲(10.69% Upside)

Andlauer Healthcare Group's strong financial performance and the positive impact of the UPS acquisition drive the stock's score. While technical indicators suggest a neutral trend, the overvaluation concerns temper the overall outlook.

Positive Factors

Strategic Positioning

The company is well-positioned to capitalize on favorable market conditions.

Negative Factors

Earnings

The company's Q1/25 EPS missed expectations, partly due to a seasonally weak quarter.

Financial Performance

Q1/25 results were negatively impacted by elevated retail bad debt expenses.

Andlauer Healthcare Group Business Overview & Revenue Model

Company Description

Andlauer Healthcare Group (AND) is a Canadian company that specializes in providing a comprehensive suite of transportation and logistics services tailored to the healthcare sector. The company operates primarily in two segments: Specialized Transportation and Healthcare Logistics. Its core services include temperature-controlled transportation, logistics services, warehousing, and distribution, which ensure the safe and compliant handling of pharmaceuticals, medical devices, and other healthcare products. With a focus on quality and reliability, Andlauer Healthcare Group supports its clients in navigating the complexities of the healthcare supply chain.

How the Company Makes Money

Andlauer Healthcare Group generates revenue through a diversified model that includes specialized transportation services and healthcare logistics solutions. In the transportation segment, the company earns money by offering temperature-controlled and time-sensitive transportation services for healthcare products. This involves leveraging a fleet of vehicles equipped to handle delicate medical goods, ensuring timely and compliant delivery. In the logistics segment, revenue is derived from providing warehousing, inventory management, and distribution services that cater specifically to the healthcare industry. These offerings are enhanced by strategic partnerships with healthcare providers and manufacturers, enabling Andlauer to integrate seamlessly into clients' supply chains and support their operational needs. The company’s focus on the healthcare sector allows it to capitalize on the growing demand for specialized logistics solutions, driven by increasing regulatory requirements and the expansion of healthcare services.

Andlauer Healthcare Group Financial Statement Overview

Summary

Andlauer Healthcare Group demonstrates strong financial health with consistent revenue growth, robust profitability, and a sound balance sheet. Despite an increase in debt levels, the company efficiently converts income into cash, supporting its operations and growth.

Income Statement

The company has shown consistent revenue growth with the TTM revenue at CAD 655.43 million, up from CAD 650.48 million in the previous year. Gross profit margin remains stable at approximately 22.9% in the TTM. The net profit margin has improved to 10.64% in the TTM, reflecting stronger profitability. EBIT and EBITDA margins are robust at 14.38% and 26.06% respectively, indicating efficient operational management. The overall trajectory is positive with healthy profitability metrics.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.41 in the TTM, indicating moderate leverage. Return on Equity (ROE) is healthy at 15.72%, showcasing effective utilization of equity. The equity ratio stands at 62.31%, suggesting a strong capital structure with adequate equity to cover liabilities. The company's balance sheet is solid, although the increasing debt levels in the TTM warrant monitoring.

Cash Flow

The company exhibits strong cash flow generation with TTM operating cash flow of CAD 124.24 million and free cash flow of CAD 105.79 million. Free cash flow growth is modest at 1.7% compared to the previous year, but the operating cash flow to net income ratio is a robust 1.78, indicating excellent cash conversion efficiency. The cash flow position is solid, providing flexibility for future investments or debt repayment.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	650.48M	647.95M	648.42M	440.12M	314.34M
Gross Profit	147.20M	147.48M	158.85M	110.75M	79.55M
EBITDA	166.72M	166.96M	175.07M	154.91M	79.20M
Net Income	64.47M	66.14M	76.28M	89.95M	37.71M
Balance Sheet
Total Assets	696.92M	682.43M	712.46M	644.17M	252.80M
Cash, Cash Equivalents and Short-Term Investments	40.48M	59.74M	65.86M	24.99M	30.15M
Total Debt	181.21M	127.90M	163.29M	187.25M	129.61M
Total Liabilities	265.78M	212.86M	271.47M	292.05M	158.47M
Stockholders Equity	431.13M	469.57M	440.99M	352.12M	94.33M
Cash Flow
Free Cash Flow	104.02M	78.83M	109.17M	74.42M	45.56M
Operating Cash Flow	124.40M	104.42M	137.13M	84.09M	51.00M
Investing Cash Flow	-18.86M	-23.85M	-45.56M	-183.38M	-20.37M
Financing Cash Flow	-126.24M	-86.18M	-51.59M	93.89M	-19.20M

Andlauer Healthcare Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 53.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AND, the sentiment is Positive. The current price of 53.3 is above the 20-day moving average (MA) of 53.18, above the 50-day MA of 52.85, and above the 200-day MA of 46.23, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 58.58 is Neutral, neither overbought nor oversold. The STOCH value of 84.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AND.

Andlauer Healthcare Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CJT	77 Outperform	$1.58B	11.07	19.73%	1.37%	14.37%	―
AND	76 Outperform	$2.09B	31.01	15.64%	0.86%	0.34%	10.40%
Sector *	62 Neutral	C$7.32B	1.75	10.22%	2.41%	10.46%	-7.18%
TTNM	58 Neutral	C$66.33M	―	-25.37%	5.48%	4.74%	-478.84%

Andlauer Healthcare Group Corporate Events

Andlauer Healthcare Group Reports Q2 2025 Results Amid Acquisition by UPS

Andlauer Healthcare Group reported a decrease in revenue for Q2 2025, primarily due to challenges in its US-based truckload businesses and the deconsolidation of a packaging subsidiary. Despite these challenges, the company maintained its EBITDA margin within the target range. The company is set to be acquired by UPS in an all-cash transaction valued at approximately $2.2 billion, with the transaction expected to close in the second half of the year, pending regulatory approval.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$42.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

Andlauer Healthcare Group’s Acquisition by UPS Affiliate Approved

Andlauer Healthcare Group has received a final order from the Ontario Superior Court of Justice approving its acquisition by a UPS affiliate for C$55.00 per share. The transaction is expected to conclude in the latter half of the year, pending approval under the Canadian Competition Act and fulfillment of customary conditions. This acquisition marks a significant development for AHG, potentially enhancing its market presence and operational capabilities within the healthcare supply chain sector.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$42.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

Andlauer Healthcare Group Secures Shareholder Approval for UPS Acquisition

Andlauer Healthcare Group has received shareholder approval for its acquisition by UPS at a rate of C$55.00 per share, following an overwhelmingly favorable vote at a special meeting. The transaction, which is pending final court approval and regulatory clearances, signifies a strategic move that could enhance AHG’s market positioning and operational capabilities within the healthcare logistics industry.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$45.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

Andlauer Healthcare Group Declares Q2 Dividend

Andlauer Healthcare Group Inc. has announced a second quarter dividend of $0.12 per share for both subordinate and multiple voting shares, payable on July 15, 2025. This announcement reflects the company’s continued commitment to providing shareholder value and may enhance its attractiveness to investors, reinforcing its position in the healthcare logistics and transportation industry.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$44.50 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

Andlauer Healthcare Group Announces Shareholder Meeting for UPS Acquisition

Andlauer Healthcare Group has announced the availability of its management information circular related to a special meeting where shareholders will vote on a resolution for UPS to acquire all outstanding shares at C$55.00 per share. The acquisition plan has strong support from major shareholders, representing approximately 82.4% of the total voting power. The Ontario Superior Court of Justice has issued an interim order authorizing the meeting, and the final arrangement is subject to court approval and regulatory clearances. A potential Canada Post labor disruption may delay the delivery of meeting materials to some Canadian shareholders, but electronic access is available.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$42.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.